<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0003613'>Antiphospholipid antibodies</z:hpo> in patients with "<z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e>" may be directed at least in part against plasma <z:chebi fb="0" ids="16247">phospholipid</z:chebi>-binding proteins, such as beta 2-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I or prothrombin, which are involved in the control of <z:mp ids='MP_0005048'>thrombosis</z:mp> and haemostasis </plain></SENT>
<SENT sid="1" pm="."><plain>IgG-class antibodies against prothrombin and beta 2-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I were measured by enzyme-linked immunoassay in initially healthy middle-aged dyslipidaemic men (non-<z:chebi fb="6" ids="39025">high-density lipoprotein</z:chebi> &gt; 5.2 mml/l) </plain></SENT>
<SENT sid="2" pm="."><plain>Serum samples had been drawn at entry to a 5-year coronary primary-prevention trial with <z:chebi fb="0" ids="5296">gemfibrozil</z:chebi> from 106 subjects who experienced either a non-fatal <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> or cardiac <z:hpo ids='HP_0011420'>death</z:hpo> during the follow-up and from 106 subjects without coronary episodes, matched for treatment group (<z:chebi fb="0" ids="5296">gemfibrozil</z:chebi>/placebo) and geographical area </plain></SENT>
<SENT sid="3" pm="."><plain>The antiprothrombin antibody level, as expressed in optical density units, was significantly higher in patients than in controls (0.26 +/- 0.17 versus 0.22 +/- 0.09; p &lt; 0.02) </plain></SENT>
<SENT sid="4" pm="."><plain>A high level of antiprothrombin antibodies (highest tertile of distribution) predicted a 2.5-fold increase in the risk (95% confidence interval 1.2-5.3) of <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> or cardiac <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>The distribution of IgG-class antibodies against beta 2-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I did not differ significantly between cases and controls </plain></SENT>
<SENT sid="6" pm="."><plain>The joint effect of antiprothrombin antibodies and other factors associated with hypercoagulative state: <z:chebi fb="0" ids="17855">triglyceride</z:chebi> level, <z:chebi fb="1" ids="6495">lipoprotein</z:chebi>(a) and smoking, was multiplicative for the risk </plain></SENT>
<SENT sid="7" pm="."><plain>Antiprothrombin antibodies are a new immunological predictor of <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> and the effect of these antibodies may be mediated by hypercoagulative mechanisms </plain></SENT>
</text></document>